Article
Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.
Molecular systems biology - 1 Oct 2020
Gillies Taryn E, Pargett Michael, Silva Jillian M, Teragawa Carolyn K, McCormick Frank, Albeck John G
Abstract excerpt
Activating mutations in RAS are present in ~ 30% of human tumors, and the resulting aberrations in ERK/MAPK signaling play a central role in oncogenesis. However, the form of these signaling changes is uncertain, with activating RAS mutants linked to both increased and decreased ERK activation in vivo. Rationally targeting the kinase activity of this pathway requires clarification of the quantitative effects of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.